Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for roughly 80% to 85% of all lung cancer diagnoses. It develops from the cells lining the airways and air sacs of the lungs and behaves differently from its less common counterpart, small cell lung cancer, which tends to grow and spread faster. NSCLC encompasses several subtypes, each with distinct characteristics that influence where tumors form, how they’re detected, and how they respond to treatment.
The Three Main Subtypes
NSCLC isn’t a single disease. It’s an umbrella term for three primary subtypes, each arising from different cells along the respiratory tract.
Adenocarcinoma is the most common subtype. It develops in the cells that line the lung’s tiny air sacs, the ones responsible for producing mucus and other substances. Because these tumors typically grow in the outer edges of the lungs, they can reach a significant size before causing symptoms like coughing or shortness of breath. Adenocarcinoma is also the type most frequently found in people who have never smoked, making up 50% to 60% of lung cancers in that group.
Squamous cell carcinoma usually starts near the central airways, the large bronchi closer to the middle of the chest. It has a stronger association with smoking than adenocarcinoma does. Because of its central location, it may cause symptoms like coughing or airway obstruction earlier in the disease.
Large cell carcinoma can appear anywhere in the lung and tends to grow quickly. It’s the least common of the three subtypes and is sometimes diagnosed when tumor cells don’t fit the patterns of adenocarcinoma or squamous cell carcinoma under a microscope.
Risk Factors Beyond Smoking
Smoking remains the leading cause of lung cancer overall, but NSCLC develops in nonsmokers more often than many people realize. The CDC estimates that secondhand smoke contributes to roughly 7,300 lung cancer deaths per year among nonsmokers in the United States, and radon exposure accounts for about 2,900 more. Radon is a naturally occurring gas that seeps into homes through foundations and can accumulate to dangerous levels without any noticeable odor or color.
Other environmental exposures that raise risk include asbestos, arsenic, diesel exhaust, certain forms of silica and chromium, and general air pollution. Air pollution has been specifically linked to tumors driven by certain genetic changes in the KRAS gene. A personal or family history of lung cancer also increases risk, and people who develop lung cancer without a smoking history are more likely to carry specific DNA mutations, particularly in the EGFR gene, that can actually open the door to targeted treatments.
Symptoms in Early Versus Advanced Stages
NSCLC is notoriously quiet in its early stages. About 7% to 10% of cases are discovered by accident, when a chest X-ray or CT scan done for an unrelated reason reveals a tumor. Only about 20% of patients have localized disease at the time of diagnosis. The rest, roughly two-thirds to three-quarters, aren’t diagnosed until the cancer has reached an advanced stage.
When early symptoms do appear, they’re easy to dismiss: a persistent cough, mild shortness of breath, or chest discomfort. Adenocarcinomas, because they grow in the lung’s periphery, are especially likely to remain silent until they’ve already spread.
Advanced NSCLC is a different picture. Weight loss, obvious breathing difficulty, and fatigue become more prominent. About one-third of patients first show up with symptoms caused by distant spread. The most common sites of metastasis are the bones, liver, adrenal glands, and brain. A person might experience bone pain, persistent headaches, or neurological changes before anyone suspects lung cancer. Tumors growing near central structures in the chest can press on nerves and blood vessels, causing hoarseness, swelling of the face and neck, or difficulty swallowing.
How NSCLC Is Staged
Staging describes how far the cancer has spread and is the single biggest factor in determining treatment options and prognosis.
- Stage I: The tumor is 3 cm or smaller (up to 4 cm in some Stage IB cases), hasn’t reached any lymph nodes, and hasn’t spread beyond the lung.
- Stage II: The tumor is typically between 3 and 7 cm, or it has spread to lymph nodes within the same lung, but not to distant sites.
- Stage III: The tumor may be larger than 7 cm or may have grown into nearby structures like the heart, windpipe, or esophagus. Cancer has spread to lymph nodes in the center of the chest or above the collarbone, but not to distant organs.
- Stage IV: The cancer has spread to distant sites: the other lung, fluid around the lungs or heart, or organs like the liver, bones, or brain.
Diagnosis and Genetic Testing
After imaging suggests a possible lung tumor, confirming the diagnosis requires a biopsy. Traditionally this means removing a small tissue sample through a needle or surgical procedure. Tissue biopsy remains the gold standard, but it has limitations: the procedure is invasive, some tumors sit in locations that are difficult or risky to reach, and the sample collected may not capture the full genetic diversity of the tumor.
Liquid biopsy has become an increasingly important alternative, particularly for advanced disease. It works by detecting fragments of tumor DNA circulating in the bloodstream. Results come back dramatically faster, with a median turnaround of about 10 days compared to 36 days for tissue-based genetic testing in one study. Liquid biopsy also identified treatment-relevant genetic markers in 76.5% of patients, compared to 54.9% with a tissue-first approach. For the standard markers that guide treatment decisions, liquid biopsy agreed with tissue results 95% to 100% of the time. In practice, doctors now base the majority of their initial treatment decisions on liquid biopsy results when both are available.
The reason genetic testing matters so much in NSCLC is that specific mutations dictate which treatments will work. Tumors are routinely tested for changes in genes like EGFR, ALK, KRAS, ROS1, RET, MET, and BRAF. These mutations are far more common in adenocarcinomas than in squamous cell carcinomas.
Treatment Approaches
How NSCLC is treated depends heavily on the stage at diagnosis and the tumor’s genetic profile. Early-stage cancers (Stages I and II) are typically treated with surgery to remove the tumor, sometimes followed by additional therapy to reduce the chance of recurrence. Stage III disease often involves a combination of radiation and systemic treatments.
Targeted Therapy
For tumors that carry specific genetic mutations, targeted drugs can block the exact molecular signals driving cancer growth. EGFR-positive NSCLC, for example, is now treated with drugs called tyrosine kinase inhibitors that zero in on the faulty protein produced by the mutated gene. Osimertinib, a third-generation version of these drugs approved in 2015, marked a turning point in treatment and remains a standard option either alone or in combination with chemotherapy. Newer combinations pairing different targeted agents together have shown improved survival in clinical trials and are expanding the choices available.
KRAS G12C, the most common actionable mutation in one large profiling study at 53.6%, now has its own class of targeted drugs. Less frequent but still treatable mutations include MET gene changes (found in roughly 7% to 8% of tested patients), along with ALK, ROS1, RET, and BRAF alterations.
Immunotherapy
For patients whose tumors don’t carry a targetable mutation, immunotherapy has transformed the treatment landscape. These drugs work by removing a “brake” that cancer cells use to hide from the immune system. The most widely used immunotherapy agents for NSCLC target either the PD-1 protein on immune cells or the PD-L1 protein on tumor cells. How much PD-L1 a tumor produces helps predict whether immunotherapy alone will be effective or whether it needs to be combined with chemotherapy.
Survival Rates by Stage
Five-year survival rates for NSCLC have improved meaningfully in recent years, driven by earlier detection through low-dose CT screening and the expansion of targeted and immunotherapy options. Based on data from patients diagnosed between 2015 and 2021, the five-year relative survival rates break down as follows:
- Localized (confined to the lung): 67%
- Regional (spread to nearby lymph nodes): 40%
- Distant (spread to other organs): 12%
- All stages combined: 32%
These numbers reflect averages across all patients in those categories, including people diagnosed years ago who didn’t have access to the newest treatments. Someone diagnosed today with a treatable genetic mutation or strong response to immunotherapy may fare considerably better than these averages suggest. The gap between localized and distant survival underscores why catching NSCLC early, before symptoms appear, makes such a significant difference in outcomes.